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Summary
Background—The WHO classification separates mastocytosis into distinct variants, but 
prognostication remains a clinical challenge. The aim of this study was to improve prognostication 
for patients with mastocytosis.
Methods—We analysed data of the registry of the European Competence Network on 
Mastocytosis including 1639 patients (age 17–90 years) diagnosed with mastocytosis according to 
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WHO criteria between Jan 12, 1978, and March 16, 2017. Univariate and multivariate analyses 
with Cox regression were applied to identify prognostic variables predicting survival outcomes 
and to establish a prognostic score. We validated this International Prognostic Scoring System in 
Mastocytosis (IPSM) with data of 462 patients (age 17–79 years) from the Spanish network Red 
Española de Mastocitosis diagnosed between Jan 22, 1998, and Nov 2, 2017.
Findings—The prognostic value of the WHO classification was confirmed in our study 
(p<0·0001). For patients with non-advanced mastocytosis (n=1380), we identified age 60 years or 
older (HR 10·75, 95% CI 5·68–20·32) and a concentration of alkaline phosphatase 100 U/L or 
higher (2·91, 1·60–5·30) as additional independent prognostic variables for overall survival. The 
resulting scoring system divided patients with non-advanced mastocytosis into three groups: low 
(no risk factors), intermediate 1 (one risk factor), and intermediate 2 (two risk factors). Overall 
survival and progression-free survival differed significantly among these groups (p<0·0001). In 
patients with advanced mastocytosis (n=259), age 60 years or older (HR 2·14, 95% CI 1·42–3·22), 
a concentration of tryptase 125 ng/mL or higher (1·81, 1·20–2·75), a leukocyte count of 16 × 109 
per L or higher (1·88, 1·27–2·79), haemoglobin of 11 g/dL or lower (1·71, 1·13–2·57), a platelet 
count of 100 × 109 per L or lower (1·63, 1·13–2·34), and skin involvement (0·46, 0·30–0·69) were 
prognostic variables. Based on these variables, a separate score for advanced mastocytosis with 
four risk categories was established, with significantly different outcomes for overall survival and 
progression-free survival (p<0·0001). The prognostic value of both scores was confirmed in 413 
patients with non-advanced disease and 49 with advanced mastocytosis from the validation cohort.
Interpretation—The IPSM scores for patients with non-advanced and advanced mastocytosis 
can be used to predict survival outcomes and guide treatment decisions. However, the predictive 
value of the IPSM needs to be confirmed in forthcoming trials.
Funding—Austrian Science Fund, Deutsche Forschungsgemeinschaft, Koeln Fortune Program, 
Charles and Ann Johnson Foundation, Instituto de Salud Carlos III, Fondos FEDER, Research-
Foundation Flanders/Fonds Wetenschappelijk Onderzoek, Clinical Research-Fund of the 
University Hospitals Leuven, and Research-Foundation Flanders/Fonds Wetenschappelijk 
Onderzoek.
Introduction
The term mastocytosis denotes a heterogeneous group of disorders characterised by 
abnormal expansion and accumulation of mast cells in various organs. The estimated 
prevalence of systemic mastocytosis is one case in 10 000 adults, and the estimated 
incidence amounts to one new case per 100 000 people per year.1 A diagnosis of 
mastocytosis is based on criteria provided by WHO.2,3 The WHO classification includes 
several prognostic variables and represents a well-established diagnostic method with 
prognostic effect. However, prognosis and survival outcomes of patients vary substantially 
among cases, even within WHO entities,4,5 and prediction of the clinical course and survival 
outcomes in individual patients is difficult. Based on the WHO classification, mastocytosis 
can essentially be split into non-advanced disease and advanced systemic disease.2, 3 Non-
advanced mastocytosis includes patients with cutaneous mastocytosis, indolent systemic 
mastocytosis, and smouldering systemic mastocytosis. These patients usually have a stable 
clinical course and a good prognosis.4 By contrast, advanced systemic mastocytosis includes 
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patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated 
haematological neoplasm, and mast cell leukaemia. These patients have a poor prognosis.
4, 6–9 Awareness of differences in disease biology and prognosis of patients with non-
advanced mastocytosis and advanced systemic mastocytosis is important.
During the past two decades, several clinical, serological, cytomorphological, 
immunological, and molecular variables have been reported to be of prognostic significance 
in mastocytosis.10–19 Several of these variables have been included in the WHO 
classification, such as organomegaly or cytopenias.2,3 Other adverse prognostic variables 
include absence of skin lesions, multilineage involvement with KIT Asp816Val, mutations in 
genes other than KIT (eg, SRSF2, ASXL1, or RUNX1), increased amounts of β2-
microglobulin in serum, and raised amounts of alkaline phosphatase.10,12–19 However, these 
variables were studied in smaller patients’ cohorts and without comparing all potential risk 
factors with each other in multivariate analyses. Moreover, several of these variables (eg, 
molecular profiling) are not available at all centres.
Several attempts have been made to improve prognostication of mastocytosis by establishing 
scoring systems.13,20,21 However, currently available scores are based on a limited number 
of patients and have not been validated in independent cohorts. More importantly, current 
scoring systems do not address the point that non-advanced mastocytosis and advanced 
systemic mastocytosis are completely different disease groups with divergent disease 
biology and distinct patterns of prognostic factors.13,20,21
Although the WHO classification is a well-established diagnostic approach with prognostic 
effect, advanced methods for prognostication in mastocytosis are scarce. The aim of this 
study was to confirm the prognostic effect of individual disease features and laboratory 
variables in patients with mastocytosis. Using data from the registry of the European 
Competence Network on Mastocytosis (ECNM), we identified the most discriminative 
prognostic variables and established a scoring system for use in daily practice. We also 
aimed to confirm the strength and effect of our scoring system in an independent validation 
cohort.
Methods
Study design and participants
Our study was retrospective in design and comprised two datasets, a test cohort and a 
validation cohort. We obtained data for the test cohort from the ECNM registry. We included 
patients with mastocytosis as per WHO criteria diagnosed between Jan 12, 1978, and March 
16, 2017, at 22 centres in Europe and one US centre (Stanford; appendix p 25).6 We 
excluded patients who had less than 2 days of follow-up data. The ECNM registry was 
approved by ethics committees of the participating centres. Details about the ECNM 
registry, study design, eligibility, inclusion criteria, age limits, disease categories, ethics 
approval, informed consent, and prognostic variables are provided in the appendix (pp 2–5).
We obtained data for the validation cohort from the Spanish network Red Española de 
Mastocitosis (REMA). This cohort includes patients with mastocytosis as per WHO criteria 
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diagnosed between Jan 22, 1998, and Nov 2, 2017 (appendix pp 5, 32). The REMA registry 
was approved by the ethics committees of the participating centres. In the REMA cohort, the 
following patients were excluded: patients with well-differentiated non-advanced systemic 
mastocytosis, patients with cutaneous mastocytosis but no bone marrow data, individuals 
with non-advanced systemic mastocytosis and less than 12 months of follow-up data, and 
patients with not enough data for analyses.
We excluded from the analysis of prognostic factors children (aged <17 years) with 
cutaneous mastocytosis because no bone marrow studies were available for most patients 
and because of the different disease biology of this group (in most patients, no KIT 
Asp816Val mutation is found). We also excluded patients with mast cell sarcoma because of 
the rarity of the disease and its unique pathology and pathogenesis (usually KIT Asp816Val 
is not detectable in mast cell sarcoma).
Procedures
We obtained clinical and laboratory data from both registries taken at diagnosis and during 
follow-up (appendix pp 26–29) in patients with indolent systemic mastocytosis, cutaneous 
mastocytosis (both children [aged <17 years] and adults [aged ≤17 years]), systemic 
mastocytosis with an associated haematological neoplasm, aggressive systemic 
mastocytosis, smouldering systemic mastocytosis, mast cell leukaemia, and mast cell 
sarcoma. Data were obtained retrospectively by chart review in the ECNM and REMA 
registries and were controlled regularly, with data clearing and updated follow-up once a 
year. We extracted data for survival outcomes and for variables to be considered as potential 
prognostic factors for development of the score. Details about development of the score and 
its validation are described in the appendix (p 6). In brief, only variables recorded in at least 
70% of patients were included. Based on results of the statistical evaluation (including 
univariate and multivariate Cox regression), we established the scores for patients with non-
advanced mastocytosis and advanced systemic mastocytosis.
Statistical analysis
We retrospectively analysed overall survival (time from diagnosis to death from any cause), 
progression-free survival (time from diagnosis to disease progression, defined as a shift from 
a low-risk disease category to a higher risk category), and event-free survival (time from 
diagnosis to progression or death, whichever occurred first) according to the Kaplan-Meier 
method with Mantel-Cox tests for group comparisons. Progression was defined as a shift 
from a lower risk to a higher risk category of mastocytosis. Moreover, development of an 
associated haematological neoplasm as well as the transformation of such an associated 
haematological neoplasm into a higher grade of disease (eg, from a lower grade myeloid 
malignancy such as myelodysplastic syndrome to acute myeloid leukaemia) counted as 
progression. Since mast cell leukaemia is an end-stage disease (no further progression can 
occur) and mastocytosis in the skin is a provisional diagnosis for patients with skin 
involvement but unknown or unavailable bone marrow, these two patient groups were 
excluded from the analysis of progression-free survival.
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We applied univariate Cox regression for all potentially prognostic variables. All variables 
that showed prognostic significance in univariate analyses were included in multivariate 
analyses. These analyses were done separately for patients with non-advanced mastocytosis 
(excluding children with cutaneous mastocytosis) and those with advanced systemic 
mastocytosis. We checked the proportional hazard assumption by testing the interaction to 
define whether the hazards of prognostic factors change during follow-up (depending on 
survival time reached).
Based on results obtained in multivariate analyses, we developed two prognostic scoring 
systems, one for patients with non-advanced mastocytosis and one for those with advanced 
systemic mastocytosis.
All statistical analyses were done using GraphPad Prism version 6 (GraphPad Software, San 
Diego, CA, USA) and Stata version 13.1 (StataCorp, College Station, TX, USA).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to the 
ECNM dataset and IA-T and AO had full access to the REMA dataset. The corresponding 
author had final responsibility for the decision to submit for publication.
Results
Between Jan 12, 1978, and Mar 16, 2017, 2361 patients were enrolled in the ECNM registry, 
of whom 567 were excluded because they were not followed up for long enough (figure 1). 
1794 patients had at least 2 days of follow-up data available in the ECNM registry and 
comprised the test cohort. Median age at diagnosis was 46 years (range 0·15–90). Among 
the test cohort, 1006 had indolent systemic mastocytosis, 280 had cutaneous mastocytosis 
(153 children and 127 adults), 174 had systemic mastocytosis with an associated 
haematological neoplasm, 62 had aggressive systemic mastocytosis, 53 had smouldering 
systemic mastocytosis, 23 had mast cell leukaemia, and two had mast cell sarcoma. A 
further 194 adults had typical mast cell infiltrates in the skin, but no bone marrow 
examination was done (table 1; appendix pp 30, 31).
Between Jan 22, 1998, and Nov 2, 2017, 1997 patients were collected in the REMA registry. 
1535 individuals were excluded from our analyses (figure 1); thus, the validation cohort 
consisted of 462 patients. Median age at diagnosis was 47 years (range 17–79). 384 patients 
had indolent systemic mastocytosis, 25 had systemic mastocytosis with an associated 
haematological neoplasm, 19 had aggressive systemic mastocytosis, 18 had cutaneous 
mastocytosis, 11 had smouldering systemic mastocytosis, and five had mast cell leukaemia 
(table 1; appendix pp 5, 32).
Median follow-up in the ECNM registry was 3·4 years (IQR 1·4–6·6; appendix pp 7, 9). The 
data obtained in our registry confirmed that the WHO classification defines two prognostic 
groups: non-advanced mastocytosis and advanced systemic mastocytosis. The non-advanced 
mastocytosis category comprised patients with cutaneous mastocytosis, mastocytosis in the 
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skin, indolent systemic mastocytosis, and smouldering systemic mastocytosis. The advanced 
systemic mastocytosis category consisted of patients with aggressive systemic mastocytosis, 
mast cell leukaemia, mast cell sarcoma, and systemic mastocytosis with an associated 
haematological neoplasm.
In the total cohort, median overall survival was 28·4 years (95% CI 19·5–37·0) and 10-year 
overall survival was 81·9% (95% CI 7·7–84·7). Differences in overall survival between 
WHO cohorts were significant (p<0·0001). Patients in the non-advanced mastocytosis 
category had improved prognosis compared with patients with advanced systemic 
mastocytosis (figure 2). However, subtle differences in overall survival were noted among 
patients with non-advanced mastocytosis. For example, individuals with cutaneous 
mastocytosis (both children and adults) had improved overall survival compared with all 
other subgroups, including patients with indolent systemic mastocytosis (figure 2A). No 
substantial differences were noted in overall survival when comparing cutaneous 
mastocytosis in children (n=153) and adults (n=127; appendix p 10). In patients with 
indolent systemic mastocytosis (73% with skin lesions; appendix p 30), 10-year overall 
survival was 93·5% (95% CI 90·1–95·8) and median overall survival was 28·4 years (95% CI 
24·1–32·8). 10-year overall survival was 100% for patients with cutaneous mastocytosis, 
92·5% (85·9–96·0) for those with mastocytosis in the skin, and 84·5% (61·1–84·5) for 
individuals with smouldering systemic mastocytosis, but median overall survival was not 
reached in these subgroups. Median overall survival was 5·7 years (95% CI 0·6–4·5) for 
patients with aggressive systemic mastocytosis, 1·9 years (0·0–5·2) for those with mast cell 
leukaemia, 1·1 years for one patient with mast cell sarcoma, and 2·9 years (2·5–3·3) for 
individuals with systemic mastocytosis with an associated haematological neoplasm (figure 
2A). 10-year overall survival was 44·0% (95% CI 26·6–60·1) in patients with aggressive 
systemic mastocytosis, 29·9% (10·0–53·2) in those with mast cell leukaemia, 0% for mast 
cell sarcoma, and 11·2% (7·5–12·1) for individuals with systemic mastocytosis with an 
associated haematological neoplasm. In 11 (22%) of 49 patients with non-advanced 
mastocytosis and 109 (75%) of 145 patients with advanced systemic mastocytosis, the cause 
of death was related to mastocytosis (appendix pp 7, 33).
Progression-free survival was analysed in 1577 (88%) patients after excluding patients with 
mastocytosis in the skin (n=194) and mast cell leukaemia (n=23). Progression of disease was 
observed in 88 (6%) of 1577 patients, including 39 (4%) of 1006 patients with indolent 
systemic mastocytosis, five (9%) of 53 with smouldering systemic mastocytosis, 11 (18%) 
of 62 with aggressive systemic mastocytosis, and 27 (16%) of 174 with systemic 
mastocytosis with an associated haematological neoplasm (table 1, appendix p 34). Six (2%) 
of 280 patients with cutaneous mastocytosis developed indolent systemic mastocytosis (one 
[1%] of 153 children and five [4%] of 127 adults; appendix p 34). In 32 (2%) of 1339 
patients with non-advanced mastocytosis, progression to advanced systemic mastocytosis 
was seen in 27 (3%) of 1006 patients with indolent systemic mastocytosis and five (9%) of 
53 patients with smouldering systemic mastocytosis (table 1, appendix pp 34, 35). Among 
194 patients with mastocytosis in the skin, 49 had a bone marrow examination during 
follow-up, resulting in a diagnosis of cutaneous mastocytosis in 16 patients, indolent 
systemic mastocytosis in 30, smouldering systemic mastocytosis in one, aggressive systemic 
mastocytosis in one, and systemic mastocytosis with an associated haematological neoplasm 
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in one (appendix p 36). For all patients, progression-free survival at 10 years was 88·0% 
(95% CI 85·8–91·5; appendix p 9). Differences in progression-free survival between WHO 
cohorts were significant (p<0·0001). None of the WHO groups reached median progression-
free survival during the study (figure 2B). Significant differences between WHO groups 
were also seen for event-free survival (p<0·0001; appendix pp 7, 11). Overall survival and 
progression-free survival in patients with systemic mastocytosis with an associated 
haematological neoplasm, according to subtype of neoplasm, are shown in the appendix (p 
12).
In patients with indolent systemic mastocytosis or smouldering systemic mastocytosis, 
alkaline phosphatase of 100 U/L or higher was associated with a significantly increased risk 
of disease progression to advanced systemic mastocytosis (appendix p 37). Age 60 years or 
older (HR 4·90, 95% CI 2·51–9·40) and alkaline phosphatase of 100 U/L or higher (2·10, 
1·07–4·05) were identified as significant (independent) predictors of evolution to higher 
grade mastocytosis in patients with non-advanced systemic mastocytosis; these same 
variables were also predictive of overall survival (HR 10·75, 95% CI 5·68–20·32; and 2·91, 
1·60–5·30, respectively; table 2). Based on these variables, we established a simple score, 
the International Prognostic Scoring System for Mastocytosis (IPSM), and applied it in 1058 
of 1380 patients with non-advanced mastocytosis in whom data for all relevant prognostic 
variables were available. Patients with non-advanced mastocytosis without additional risk 
factors comprised the low-risk group (median age 43 years), and those with one or two risk 
factors formed the intermediate-risk group 1 (referred to as int-1; median age 56 years) and 
intermediate risk-group 2 (referred to as int-2; median age 64 years), respectively.
Overall survival at 10 years was 98·1% (95% CI 95·2–99·3) in the low-risk group, 87·1% 
(77·2–91·9) in the int-1 group, 52·1% (29·4–70·7) in the int-2-risk group, and 22·0% (13·9–
21·2) in patients with advanced systemic mastocytosis (p<0·0001; figure 3A). Significant 
differences were also observed in progression-free survival at 10 years: 96·3% (95% CI 
92·2–98·3) in lowrisk patients, 86·7% (77·9–92·2) in int-1 patients, 76·3% (52·2–89·4) in 
int-2 patients, and 61·1% (42·0–75·6) in patients with advanced systemic mastocytosis 
(figure 3B). The significance of the score was also confirmed for overall survival in 
mastocytosis in the skin and indolent systemic mastocytosis (p<0·0001) and for progression-
free survival in cutaneous mastocytosis (p<0·0001), indolent systemic mastocytosis 
(p=0·0006), and smouldering systemic mastocytosis (p=0·0011; appendix pp 13, 14). In 
patients with smouldering systemic mastocytosis, the differences in overall survival were not 
significant (p=0·093), which might be attributable to the relatively low number of patients 
with this disorder. The score was also of prognostic significance regarding event-free 
survival in all subgroups (appendix pp 8, 15, 16).
In patients with advanced systemic mastocytosis, age 60 years or older (HR 2·14, 95% CI 
1·42–3·22), tryptase 125 ng/mL or higher (1·81, 1·20–2·75), leukocytes 16 × 109 per L or 
higher (1·88, 1·27–2·79), haemoglobin 11 g/dL or lower (1·71, 1·13–2·57) platelets 100 × 
109 per L or lower (1·63, 1·13–2·34), and skin involvement (0·46, 0·30–0·69) were 
independent prognostic factors for overall survival in multivariate analyses (table 2). These 
variables were used to optimise scoring in patients with advanced systemic mastocytosis. 
The score was applied in 229 (88%) of 259 patients for whom data for all variables were 
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available. Every risk factor with an HR greater than 1·50 scored 1 point, and risk factors 
with an HR of 0·50 or lower scored –1 point. By adding all risk points, four different risk 
groups were established. Patients with scores from –1 to 0 points (no risk factors) were 
grouped in advanced systemic mastocytosis 1 (referred to as AdvSM-1), those with a score 
of 1 point (one risk factor) were in the advanced systemic mastocytosis 2 (AdvSM-2) group, 
individuals with scores of 2–3 points (two or three risk factors) were grouped in advanced 
systemic mastocytosis 3 (AdvSM-3), and patients with a score of 4 or 5 points (four or five 
risk factors) were included in the advanced systemic mastocytosis 4 (AdvSM-4) group.
These groupings were of prognostic significance for overall survival (p<0·0001; figure 3C). 
Overall survival of patients in risk groups AdvSM-1 and AdvSM-2 was similar to that of 
patients with non-advanced mastocytosis in the int-1 and int-2 risk groups, respectively 
(figure 3C). The significance of the score for advanced systemic mastocytosis was also 
confirmed for progression-free survival and event-free survival (p<0·0001; figure 3D; 
appendix p 17) and for the individual WHO entities of aggressive systemic mastocytosis, 
mast cell leukaemia, and systemic mastocytosis with an associated haematological neoplasm 
(appendix pp 18–20).
The IPSM was validated using data from the REMA registry for 413 (89%) patients with 
non-advanced mastocytosis and 49 (11%) with advanced systemic mastocytosis. Both scores 
showed significant results in the validation sample (p<0·0001 for overall survival, p<0·0001 
for progression-free survival, and p<0·0001 for event-free survival), confirming the 
prognostic value and usefulness of the IPSM (appendix pp 21–23).
Discussion
Using data from a large cohort of patients in the ECNM registry, we identified independent 
prognostic variables for patients with non-advanced mastocytosis (age and alkaline 
phosphatase) and advanced systemic mastocytosis (tryptase, blood counts, and absence of 
skin involvement). Based on these variables, we established a simple prognostic score 
system, referred to as IPSM. The predictive value of this new score was confirmed in an 
independent validation cohort provided by the REMA.
So far, it remains unknown whether adults with cutaneous mastocytosis have a favourable 
outcome compared to patients with indolent systemic mastocytosis. In our study, patients 
with adulthood cutaneous mastocytosis had good overall survival, which was similar to that 
recorded in children with cutaneous mastocytosis and improved compared with overall 
survival of patients with indolent systemic mastocytosis or mastocytosis in the skin. The 
improved overall survival seen in children and adults with cutaneous mastocytosis could be 
explained by the lower numbers of cases with disease progression. Patients with 
mastocytosis in the skin and indolent systemic mastocytosis had similar overall survival, 
suggesting that most patients with mastocytosis in the skin might indeed suffer from 
indolent systemic mastocytosis, whereas adults with cutaneous mastocytosis have a better 
prognosis. So far, it remains unknown why adults with cutaneous mastocytosis have a better 
overall survival compared to patients with indolent systemic mastocytosis or mastocytosis in 
the skin. One explanation could be that indolent systemic mastocytosis is a more advanced 
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disease with higher risk of progression to advanced systemic mastocytosis. An alternative 
explanation could be the higher median age of patients with mastocytosis in the skin (age 43 
years) and indolent systemic mastocytosis (age 47 years) compared to adults with cutaneous 
mastocytosis (age 37 years).
Several clinical and laboratory parameters are prognostic variables for mastocytosis.
7,10,12–19 In our study, amounts of alkaline phosphatase 100 U/L or higher and age 60 years 
or older were the two major independent predictors of survival in patients with non-
advanced mastocytosis and were used to establish the IPSM. Alkaline phosphatase has 
already been shown to be of prognostic value in systemic mastocytosis in previous studies.
12,13,20 A rise in the amount of alkaline phosphatase could reflect mastocytosis-mediated 
organ damage in the bones, liver, or both.13,20 High amounts of alkaline phosphatase found 
in some patients with non-advanced mastocytosis might, therefore, indicate clinically silent 
organ involvement. Such occult organ involvement could produce raised amounts of alkaline 
phosphatase even before the disease progresses to advanced systemic mastocytosis. Indeed, 
we found significantly more progressions in indolent or smouldering systemic mastocytosis 
to advanced systemic mastocytosis in patients with amounts of alkaline phosphatase of 100 
U/L or higher. Surprisingly, in patients with advanced systemic mastocytosis, alkaline 
phosphatase was not of prognostic value, contrasting with findings of previous studies.
13,20–22 However, in previous studies, the prognostic value of alkaline phosphatase was 
examined in the overall cohort of patients with non-advanced mastocytosis and advanced 
systemic mastocytosis,20,21 whereas in our study, patients with non-advanced mastocytosis 
and advanced systemic mastocytosis were analysed separately. Amounts of alkaline 
phosphatase might also fluctuate over time in individual patients, which could represent a 
limitation of this variable. However, a constantly increasing amount of alkaline phosphatase 
must raise suspicion of disease progression.
Analysing the median age of our patients, we saw that low-risk patients were younger (age 
43 years) than patients in the int-1 group (age 56 years) and the int-2 group (age 64 years). A 
simple explanation for this observation could be that reduced life expectancy is mainly 
attributable to the older age of these patients. However, not only overall survival but also 
progression-free survival significantly differed among these patients. Thus, our results 
cannot only be accounted for by differences in the natural age-dependent life expectancy. 
With respect to progression-free survival, increased clonal instability in advanced age might 
contribute to higher progression rates. Indeed, the number of mutations in haemopoietic 
stem cells increases with age.23
Organomegaly has been shown to be of prognostic importance in systemic mastocytosis.
13,20 In our study, organomegaly was not an independent prognostic factor for overall 
survival, which could be accounted for by the fact that organomegaly is represented in the 
WHO classification as either a B finding (ie, without organ damage) or as a C finding (ie, 
with organ damage caused by neoplastic mast cell infiltration).2,3
Patients with advanced systemic mastocytosis sometimes do not have skin involvement.2,3 In 
our study, the absence of skin lesions was of prognostic importance in the multivariate 
analysis of patients with advanced systemic mastocytosis, but not in the multivariate analysis 
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of patients with non-advanced mastocytosis. This result has several explanations. First, it is 
well known that skin lesions are preferentially absent in patients with rapidly progressive 
aggressive systemic mastocytosis and mast cell leukaemia. Second, a subgroup of patients 
with indolent systemic mastocytosis have no skin lesions and their clinical course remains 
stable. Contrasting patients with advanced systemic mastocytosis, individuals with indolent 
systemic mastocytosis without skin lesions have a low mast cell burden and a favourable 
prognosis and are currently classified as isolated bone marrow mastocytosis as per the WHO 
classification.2,3
In patients with advanced systemic mastocytosis, disease biology and predictive variables 
are different from those of patients with non-advanced mastocytosis. Therefore, we analysed 
the effect of potential prognostic factors in patients with advanced systemic mastocytosis 
separately. Again, age was of prognostic importance. Other prognostic independent variables 
in patients with advanced systemic mastocytosis included elevated tryptase, abnormal blood 
counts, and absence of skin involvement. Using these variables, patients with advanced 
systemic mastocytosis were split into four risk groups, with significant differences with 
respect to overall survival, event-free survival, and progression-free survival. The prognosis 
of patients in the int-1 and int-2 risk groups overlapped with that of patients in the AdvSM-1 
and AdvSM-2 groups, respectively. This observation supports the strengths and clinical 
relevance of the IPSM. Thus, the IPSM might identify patients at higher risk than expected 
by WHO classification.
Several attempts have been made to develop prognostic scoring systems in mastocytosis.
13,20,21 However, these scores have limitations. First, most score studies have included 
relatively low numbers of patients and no validation cohort.13,20,21 Second, most of these 
studies did not take the different disease biology of non-advanced mastocytosis and 
advanced systemic mastocytosis into account. Moreover, these score models are based on 
datasets that include more than 50% of patients with advanced systemic mastocytosis, 
whereas in our cohort only 15% of all patients had advanced systemic mastocytosis, which 
is closer to the real-life situation (appendix p 39).13,20,21 The strength of the IPSM is that it 
is based on an unbiased statistical approach in more than 1000 patients, including all WHO 
variants of systemic mastocytosis at frequencies seen in daily practice. Moreover, prognostic 
factors were ascertained separately in patients with non-advanced mastocytosis and 
advanced systemic mastocytosis to establish optimal scoring models for both cohorts. 
Finally, our score was validated by an independent cohort from the REMA registry. The fact 
that the ECNM registry contains patients from many different centres and, thus, all 
categories of the disease in a rather balanced form also supports the strength of the IPSM. 
The IPSM incorporates the WHO classification and a few other simple variables, which 
provides a practicable method ready for use in patients with non-advanced mastocytosis and 
advanced systemic mastocytosis.
Other prognostic variables have been analysed previously in patients with systemic 
mastocytosis. Elevated β2-microglobulin, multilineage involvement, the KIT Asp816Val 
allele burden, and mutations in additional genes are of prognostic importance.13–16,24 Some 
of these markers, including β2-microglobulin or multilineage involvement, are not measured 
in daily practice in most centres, as confirmed by our study. Moreover, KIT Asp816Val is 
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often analysed by conventional PCR but not by quantitative PCR. Other molecular markers 
were only available for a few patients in the ECNM registry, which shows that their use is 
still restricted to specialised centres. Moreover, molecular abnormalities are preferentially 
detected in patients who have advanced systemic mastocytosis, such as systemic 
mastocytosis with an associated haematological neoplasm, and are, therefore, not always 
WHO-independent variables. Finally, no standardised methodology for mutation analysis in 
mastocytosis is available to date. Nevertheless, such additional variables, and multilineage 
involvement, will soon be standardised and could support prognostication in the future.
In patients with non-advanced mastocytosis, progression to high-risk mastocytosis is a rare 
event and quality of life is most important and probably the key variable to look at when 
planning treatment.25,26 Indeed, most patients die from causes other than mastocytosis. 
However, it is important to identify those few cases who are at risk to progress after some 
time. Since patients with non-advanced mastocytosis in the int-1 or int-2 risk groups have a 
higher risk of progression to advanced systemic mastocytosis, these patients need to be 
monitored closely to detect progression and to define the right time for intervention.
Considering the availability of new disease-modifying approaches in advanced systemic 
mastocytosis, our score could be important for making treatment decisions in daily practice: 
first, the WHO-based diagnosis is established and, second, our score is applied. Patients with 
advanced systemic mastocytosis usually need cytoreductive treatment, but the exact type of 
treatment depends on patient-related factors, disease aggressiveness, and the presence or 
type of associated haematological neoplasm.27 At present, therapeutic options for slowly 
progressing advanced systemic mastocytosis include (offlabel) interferon alfa, cladribine, 
and midostaurin, which was approved for use by the US Food and Drug Administration and 
the European Medicines Agency in advanced systemic mastocytosis in 2017.27–29 By 
contrast, in patients with advanced systemic mastocytosis with rapid progression or mast cell 
leukaemia, polychemotherapy and, if possible, haemopoietic stem-cell transplantation are 
considered.30 However, the disease-modifying or curative potential of treatment has to be 
weighed against side-effects, and the IPSM might help with patients’ selection. For example, 
in older patients with slowly progressing advanced systemic mastocytosis in a low-risk 
group according to the IPSM, treatment with midostaurin or cladribine could be a reasonable 
option.29
Our study has several limitations. Because of the retrospective nature of data collection, only 
variables used in daily routine are regularly captured. Likewise, we cannot exclude that other 
markers (eg, β2-microglobulin, which was only available in 21% of all patients) would have 
added to prognostication when examined in all individuals and included in a scoring system. 
Moreover, patients are usually added to registries over a prolonged period, and diagnostic 
assays, standards, and sensitivity of molecular tests can change. Further, standards of clinical 
assessment and staging can change and might lead to earlier disease detection. For example, 
in patients with non-advanced mastocytosis, a diagnostic delay was sometimes suspected 
because first symptoms are reported by patients long before a diagnosis is established. In 
some patients, the initial diagnosis might have been cutaneous mastocytosis but, because of 
delay, the patient already had indolent systemic mastocytosis when diagnosed. However, it is 
almost impossible to prove that self-reported symptoms are related to mastocytosis. In the 
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ECNM registry, data were entered in a standardised way in a central web-based registry and 
were checked regularly for correctness and plausibility. To guarantee data quality, a yearly 
data-clearing process was done. Thus, our score is based on a robust and representative 
database.
In summary, the IPSM can optimise prognostication of patients with non-advanced and 
advanced systemic mastocytosis to better guide future interventions in these patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Evidence before the study
We searched PubMed for articles published before June 7, 2019, containing information 
about individual prognostic variables and scoring systems established in mastocytosis. 
We did not restrict our search by language or type of article. Prognostication in 
mastocytosis is based mainly on the WHO classification.
Several prognostic variables have been identified, including absence of skin lesions, 
multilineage involvement with KIT Asp816Val, mutations in genes other than KIT, raised 
amounts of β2-microglobulin in serum, or increased alkaline phosphatase. However, these 
variables have only been validated in a limited number of patients and only a few 
prognostic scoring systems are available. The Mayo score includes the WHO 
classification, age, platelet count, anaemia, alkaline phosphatase, and somatic mutations 
as major prognostic variables. Similar variables were identified and used in the 
Mannheim score. The Mayo and Mannheim scoring systems are based on a limited 
number of cases and have not been validated in independent cohorts so far. Previous 
prediction models have not addressed the important point that patients with non-advanced 
systemic mastocytosis and advanced systemic mastocytosis are subgroups of disease with 
completely different biology, disease course, survival outcomes, and patterns of 
prognostic factors.
Added value of this study
We established a new score, termed the International Prognostic Scoring System for 
Mastocytosis (IPSM), that was optimised for prognostication in patients with non-
advanced mastocytosis and advanced systemic mastocytosis. This new score improves 
prognostication when compared with the WHO classification and other scoring models. 
Validation of our score by an independent sample-cohort confirmed its prognostic value.
Implications of all the available evidence
Several clinical studies have analysed the importance of prognostic variables in patients 
with mastocytosis, and attempts have been made to develop a multiparametric scoring 
system in this disease. In these scores, multilineage involvement of leukocytes with KIT 
Asp816Val, the KIT Asp816Val allele burden, or mutations in additional genes were 
included as prognostic variables. However, such markers are only available in a few 
specialised centres. Moreover, multilineage involvement and additional molecular 
abnormalities are preferentially detected in patients who have advanced systemic 
mastocytosis; thus, the contribution of these variables is limited. We based our new 
scoring system on simple variables that are checked regularly in daily practice. The 
resulting score (IPSM) is a useful and practicable method to identify patients with a 
higher risk of progression or death than would have been expected from the WHO 
classification. As our score is simple and ready for use, it should add substantially to 
management and patients’ selection for various treatments in daily practice.
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Figure 1. Study profile
Patients were selected from the ECNM registry (A) and REMA (B). In the ECNM cohort, 
only patients with at least 2 days of follow-up were included. All patients were included in 
analyses of overall survival and event-free survival. ECNM=European Competence Network 
on Mastocytosis. REMA=Red Española de Mastocitosis. *Included in analyses of 
progression-free survival. †Children (aged <17 years) were excluded from the assessment of 
prognostic factors and development of the score because, for most children, no bone marrow 
studies were available and because the disease is different. Patients with mast cell sarcoma 
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were excluded because of the rarity of the disease and its unique pathology and 
pathogenesis. ‡Those excluded were children (aged <17 years), had cutaneous mastocytosis 
without a bone marrow study, had less than 12 months of follow-up for non-advanced 
systemic mastocytosis, or did not have enough data.
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Figure 2. Survival outcomes in WHO subgroups of mastocytosis
Kaplan–Meier curves show the probability of overall survival (A) and progression-free 
survival (B) in subgroups of patients with mastocytosis, defined by WHO criteria.
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Figure 3. Survival outcomes according to the IPSM score in patients with non-advanced and 
advanced systemic mastocytosis
Kaplan–Meier curves show the probability of overall survival (A, C) and progression-free 
survival (B, D) in patients with non-advanced and advanced systemic mastocytosis, defined 
by the IPSM.
Upper panels (A, B) show that patients with non-advanced systemic mastocytosis at low risk 
(no risk factors [low]) and intermediate risk (one [int-1] or two [int-2] additional risk 
factors) differed significantly and had a favourable outcome compared with patients with 
advanced systemic mastocytosis (AdvSM). Lower panels (C, D) show that patients with 
advanced systemic mastocytosis and no additional risk factors (AdvSM-1) differed 
significantly from those with one (AdvSM-2), two to three (AdvSM-3), or four to five 
(AdvSM-4) risk factors. IPSM=international prognostic scoring system for mastocytosis.
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